Tags

Type your tag names separated by a space and hit enter

CD6+ T cell-depleted allogeneic bone marrow transplantation for non-Hodgkin's lymphoma.
Bone Marrow Transplant. 1998 Jun; 21(12):1177-81.BM

Abstract

For patients with non-Hodgkin's lymphoma (NHL) undergoing blood or bone marrow transplantation (BMT), the use of autologous grafts has often been preferred to that of allogeneic stem cells because of a significantly lower incidence of non-relapse mortality. If complications associated with allo-BMT could be minimized without compromising efficacy, then it might become a preferred strategy for certain subsets of patients. In this report, we describe the toxicity and long-term efficacy of T cell-depleted allogeneic BMT using anti-CD6 monoclonal antibody and complement alone to reduce the risk of GVHD and its sequelae. Twenty-two patients, aged 18-60 years, with high (n = 10), intermediate (n = 9), or low (n = 3) grade NHL underwent HLA-identical allogeneic BMT from siblings. Patients had either relapsed after at least one remission or never achieved a full remission with chemotherapy. Twenty patients had a history of marrow involvement. Bone marrow was depleted of CD6+ T cells with T12 monoclonal antibody and complement as the sole form of GVHD prophylaxis. Stable hematopoietic engraftment occurred in all 22 patients. Four patients developed grade 2 and 1 patient grade 3 GVHD (23% grades 2-4 GVHD). Chronic GVHD has occurred in three patients. Treatment-related mortality was very low. Only one patient died while in remission. Thirteen patients are alive and free of disease with a median follow-up of 30 months. Estimated event-free and overall survivals are 54 and 59%, respectively. CD6 allogeneic marrow transplantation is associated with a low risk of transplant-related complications and may offer advantages for certain patients with recurrent NHL felt to be at high risk for relapse after autologous transplantation.

Authors+Show Affiliations

Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA 02115, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

9674848

Citation

Soiffer, R J., et al. "CD6+ T Cell-depleted Allogeneic Bone Marrow Transplantation for non-Hodgkin's Lymphoma." Bone Marrow Transplantation, vol. 21, no. 12, 1998, pp. 1177-81.
Soiffer RJ, Freedman AS, Neuberg D, et al. CD6+ T cell-depleted allogeneic bone marrow transplantation for non-Hodgkin's lymphoma. Bone Marrow Transplant. 1998;21(12):1177-81.
Soiffer, R. J., Freedman, A. S., Neuberg, D., Fisher, D. C., Alyea, E. P., Gribben, J., Schlossman, R. L., Bartlett-Pandite, L., Kuhlman, C., Murray, C., Freeman, A., Mauch, P., Anderson, K. C., Nadler, L. M., & Ritz, J. (1998). CD6+ T cell-depleted allogeneic bone marrow transplantation for non-Hodgkin's lymphoma. Bone Marrow Transplantation, 21(12), 1177-81.
Soiffer RJ, et al. CD6+ T Cell-depleted Allogeneic Bone Marrow Transplantation for non-Hodgkin's Lymphoma. Bone Marrow Transplant. 1998;21(12):1177-81. PubMed PMID: 9674848.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - CD6+ T cell-depleted allogeneic bone marrow transplantation for non-Hodgkin's lymphoma. AU - Soiffer,R J, AU - Freedman,A S, AU - Neuberg,D, AU - Fisher,D C, AU - Alyea,E P, AU - Gribben,J, AU - Schlossman,R L, AU - Bartlett-Pandite,L, AU - Kuhlman,C, AU - Murray,C, AU - Freeman,A, AU - Mauch,P, AU - Anderson,K C, AU - Nadler,L M, AU - Ritz,J, PY - 1998/7/23/pubmed PY - 1998/7/23/medline PY - 1998/7/23/entrez SP - 1177 EP - 81 JF - Bone marrow transplantation JO - Bone Marrow Transplant VL - 21 IS - 12 N2 - For patients with non-Hodgkin's lymphoma (NHL) undergoing blood or bone marrow transplantation (BMT), the use of autologous grafts has often been preferred to that of allogeneic stem cells because of a significantly lower incidence of non-relapse mortality. If complications associated with allo-BMT could be minimized without compromising efficacy, then it might become a preferred strategy for certain subsets of patients. In this report, we describe the toxicity and long-term efficacy of T cell-depleted allogeneic BMT using anti-CD6 monoclonal antibody and complement alone to reduce the risk of GVHD and its sequelae. Twenty-two patients, aged 18-60 years, with high (n = 10), intermediate (n = 9), or low (n = 3) grade NHL underwent HLA-identical allogeneic BMT from siblings. Patients had either relapsed after at least one remission or never achieved a full remission with chemotherapy. Twenty patients had a history of marrow involvement. Bone marrow was depleted of CD6+ T cells with T12 monoclonal antibody and complement as the sole form of GVHD prophylaxis. Stable hematopoietic engraftment occurred in all 22 patients. Four patients developed grade 2 and 1 patient grade 3 GVHD (23% grades 2-4 GVHD). Chronic GVHD has occurred in three patients. Treatment-related mortality was very low. Only one patient died while in remission. Thirteen patients are alive and free of disease with a median follow-up of 30 months. Estimated event-free and overall survivals are 54 and 59%, respectively. CD6 allogeneic marrow transplantation is associated with a low risk of transplant-related complications and may offer advantages for certain patients with recurrent NHL felt to be at high risk for relapse after autologous transplantation. SN - 0268-3369 UR - https://www.unboundmedicine.com/medline/citation/9674848/CD6+_T_cell_depleted_allogeneic_bone_marrow_transplantation_for_non_Hodgkin's_lymphoma_ L2 - https://doi.org/10.1038/sj.bmt.1701271 DB - PRIME DP - Unbound Medicine ER -